Cancer Treatment Today

Dacogen (decitabine) is a new drug, a DNA methyltransferase inhibitors (DMTI) that approved by the FDA for use in all French- American British (FAB) categories for MDS. The response rates for Dacogen were 30% (9% CR, 8% PR, 13% HI). Median TTP was prolonged from 7.8 months to 12.1 months compared to supportive care (p=0.1). Higher response rates have been reported in a single institution trial using lower doses of Dacogen. This drug is now FDA approved

Overcoming immune tolerance against tumor self-antigens is a goal of intense research in the design of cancer therapies. One approach to enhance immune system activation against tumor antigens is to bl;ock the inhibitory co-stimulatory signals mediated by cytotoxic T lymphocyte antigen 4, (CTLA-4) expressed on activated T cells. The CP-675 is one of several fully human monoclonal antibodies that are directed against human CTLA-4, ipilimumab (Medarex/Bristol-Myers

Several conditions. most commonly Castleman's with about 30% of cases, can be associated with polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes (POEMS) syndrome, or it can present by itself. High-dose chemotherapy with autologous peripheral blood stem cell transplantation (ASCT) has been reported in case reprots and there are no prospective trials and it can cause considerable peritransplant morbidity. IN 2005 Dr. Dizspenzieri

Oxycodone is a full opioid agonist with no antagonist properties whose principal therapeutic action is analgesia. It has an affinity for kappa, mu and delta opiate receptors in the brain and spinal cord. Oxycodone is similar to morphine in its action. Other pharmacological actions of oxycodone are in the CNS (respiratory depression, antitussive, anxiolytic, sedative and miosis), smooth muscle (constipation, reduction in gastric, biliary and pancreatic

Both Halaven and Exjeva are new drugs that were recently approved.   HALAVEN( eribubilin) is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. This was based on an open-label, randomized, multicenter trial of

Cxbladder is a genomic urine test that purpots to t quickly and accurately detect or rule out bladder cancer. The test combines clinical risk factor markers with genetic information, measuring five biomarker genes to detect the presence or absence of bladder cancer. There is a tried fo these tests, and Cxbladder Detect can be used as an adjunct to cystoscopy or as a substitute for other urine-based tests or imaging procedures. According to the manufacturer,

PET is being more frequenlty used to detect and identify recurrence. More recently NCCN has been more supportive of PET in this setting. It used to support PET only in the situation of rising CEA and no identified recurrence for localization of disease recurrence in patients with rising CEA level and non-diagnostic imaging studies, such as CT scans.However,  PET scan can potentially identify occult disease in this setting that CT misses. Therefore, 

The issue in is whether the docetaxel/ cyclophashamide regimen has a febrile neutropenia rate of 20% or more when used in the usual manner in adjuvant treatmetn of breast cancer. The issue is solely whether the docetaxel/ cyclophashamide regimen has a febrile neutrropenai rate of 20% or more when used in the usual manner in adjuvant treatment of breast cancer. The original Journal of Clinical Onology paper(Dec 1 206)reported a febrile nutropenia

Allogeneic stem cell transplantation is the only curative therapy for several hematologic malignancies, but the inability to identify a suitable HLA-matched donor in a timely manner can preclude the use of this potentially lifesaving procedure. Sequential clinical trials have led to the refinement of successful approaches using alternative donor sources, either combined cord blood units or haploidentical-related family members. Since teh first report

Cyclin-dependent kinase (CDK) 4/6 inhibitors are a class of anticancer medications that can reduce or eliminate endocrine resistance when used in combination with endocrine therapy for the treatment of hormone receptorpositive (HR+) breast cancer. Currently, three CDK4/6 inhibitors are approved for the initial treatment of HR+ advanced breast cancer in combination with an aromatase inhibitor (AI): abemaciclib,[1] palbociclib,[2] or ribociclib[3.